Analysts Just Made A Major Revision To Their Swiss Life Holding AG (VTX:SLHN) Revenue Forecasts

Yahoo FinanceJan 13 14:03

SWISS LIFE HOLDING AG UNSP ADR EACH REPR 1/20 ORD To Go Ex-Dividend On May 3rd, 2023 With 1.59761 USD Dividend Per Share

May 2nd - $SWISS LIFE HOLDING AG UNSP ADR EACH REPR 1/20 ORD(SZLMY.US)$ is trading ex-dividend on May 3rd, 2023. Shareholders of record on May 4th, 2023 will receive 1.59761 USD dividend per share

Futu NewsMay 2, 2023 09:03

DigitalBridge Gets $318M From First Stage of DataBank Recapitalization

DigitalBridge Group (NYSE:DBRG) closed the first stage of the previously announced recapitalization of its portfolio company, DataBank, and received $318M as a result, up from the $230M it initially e

Seeking AlphaAug 30, 2022 04:53

Swiss Life Targets Midterm Fee Growth; Plans Higher Dividend, CHF1 Bln Buyback

By Joshua Kirby Swiss Life Holding AG on Thursday set out its midterm plan targeting higher earnings and shareholder returns, as well as reductions in emissions from its operations and portfo

Dow Jones NewswiresNov 25, 2021 14:20

Fog Core Technology rose 5% again before the market, after the US FDA approved the legal sale of e-cigarette products in the US

Following a 6.51% increase last Friday, Fuxin Technology rose another 5% to 5.67 US dollars before the market today. According to the news, it is a rare “green light” for the US Food and Drug Administration to release e-cigarettes for sale in the US. In addition, Wall Street analysts recently said that Fog Core Technology currently provides electronic steam products with various value-added functions. If it continues to invest in R&D, it will provide more products, and its product revenue line will continue to grow; it is expected that Fog Core Technology's revenue will grow at a rate of 15% between 2026 and 2030; CFO (net cash flow from operating activities) /sales will maintain a 30% increase

新浪美股Oct 18, 2021 16:33

Valneva surged more than 30% before the market, and its COVID-19 vaccine phase 3 trial under development achieved positive results

Valneva (VALN.N) surged more than 30% before the market, and the phase 3 trial of its COVID-19 vaccine currently under development achieved positive results.

新浪美股Oct 18, 2021 16:23